Compare MIND & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIND | MAIA |
|---|---|---|
| Founded | 1987 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.4M | 77.1M |
| IPO Year | N/A | 2022 |
| Metric | MIND | MAIA |
|---|---|---|
| Price | $7.02 | $1.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 122.5K | ★ 547.8K |
| Earning Date | 04-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.31 | N/A |
| Revenue Next Year | $1.01 | N/A |
| P/E Ratio | $22.27 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.51 | $0.87 |
| 52 Week High | $14.50 | $3.19 |
| Indicator | MIND | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 51.35 | 47.43 |
| Support Level | $6.50 | $1.24 |
| Resistance Level | $9.22 | $1.46 |
| Average True Range (ATR) | 0.35 | 0.08 |
| MACD | 0.09 | 0.00 |
| Stochastic Oscillator | 64.72 | 33.19 |
MIND Technology Inc provides technology and solutions for exploration, survey, and defense applications in oceanographic, hydrographic, defense, seismic, and security industries. The company operates in segments namely, Seamap Marine Products and Klein Marine Products helps manufacture and sell specialized, high-performance sonar and seismic equipment. The company generates more revenue from Seamap Marine Products. The company's geographical segments include the United States; China, Norway; Turkey; Singapore; and Canada & Other.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.